Pain Therapeutics first sought approval for Remoxy in 2008 and then again in 2011. The FDA cited concerns over clinical safety, drug efficacy, manufacturing and stability as past reasons for rejection.
This time, the agency said the company needs to perform additional studies to back up proposed label claims about the drug’s abuse-resistant properties.
Pain Therapeutics said it will conduct the necessary studies before submitting Remoxy for approval for the fourth time, according to the report. Company shares fell 54 percent on Monday to $1.24 upon news of the rejection.
More aritcles on supply chain:
Mylan underreported EpiPen profits by 60% at Congressional hearing
FDA approves handheld device to assess traumatic brain injury
This company reduced shipping damages by printing flat screen TVs on their boxes
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
